Trials / Completed
CompletedNCT03082222
ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
An Open, Multicentric, Non-Interventional Observational Study Investigating Retention, Seizure Control and Tolerability in Epilepsy Patients With Partial Onset Seizures Receiving Eslicarbazepine Acetate (ESL) in Different Therapy Situations
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 246 (actual)
- Sponsor
- Eisai GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non interventional prospective study. Centers will enroll adult participants with partial onset seizures with or without secondary generalisation for whom the clinician has decided to initiate eslicarbazepine acetate (ESL) as an adjunctive therapy or monotherapy prior to the decision to take part in this study. Participants to be enrolled into the study will receive ESL either as an adjunctive therapy to one baseline antiepileptic drug (AED) or to at least two baseline AEDs or as monotherapy. Participants will be seen at baseline and at a follow-up visit after approximately 6 months to assess retention, efficacy, tolerability, quality of life (optional), and cognitive performances (optional).
Conditions
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-10-29
- Completion
- 2018-10-29
- First posted
- 2017-03-17
- Last updated
- 2019-09-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03082222. Inclusion in this directory is not an endorsement.